What the studies show
As a single diagnostic dose, flushing was the only side effect reported. Repeated-use safety is not established.
“During administration of GHRP-6, the only side effects observed were flush symptoms.”
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Petersenn S, et al. Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or with GHRH: comparison with the insulin tolerance test.Eur J Endocrinol, 2002;146:667–67220 patients; diagnostic performance equal to the ITT.
In context
GHRP-6 is the first of the growth-hormone-releasing peptides, a synthetic six-amino-acid ghrelin mimic. In studies it raises growth hormone as reliably as the standard insulin tolerance test, which makes it a useful diagnostic; it also stimulates appetite. As with the rest of its class, there is no controlled human trial showing it builds muscle or reduces fat, and it is banned in sport.
GHRP-6 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is GHRP-6 proven to cause safety in humans?
What studies are behind the grade?
Is GHRP-6 approved for this?
Other outcomes for GHRP-6
- BGrowth hormone release (diagnostic)Diagnostic comparison studies
- CAppetiteSmall human studies
- DBody compositionNone
Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →